

Eric Huselton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8807369/publications.pdf>

Version: 2024-02-01

17
papers

76
citations

1684188
5
h-index

1474206
9
g-index

18
all docs

18
docs citations

18
times ranked

106
citing authors

#	ARTICLE	IF	CITATIONS
1	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2047-2055.	2.0	18
2	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3776-3783.	7.0	14
3	A single-arm pilot study of a mobile health exercise intervention (GO-EXCAP) in older patients with myeloid neoplasms. <i>Blood Advances</i> , 2022, 6, 3850-3860.	5.2	13
4	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. <i>Leukemia Research</i> , 2021, 110, 106713.	0.8	9
5	Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS. <i>Blood</i> , 2019, 134, 3915-3915.	1.4	6
6	Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes. <i>Blood Advances</i> , 2021, 5, 5554-5564.	5.2	4
7	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 769-771.	2.4	3
8	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 1441-1449.	1.3	2
9	Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2019, 134, 4496-4496.	1.4	2
10	Protocol for a pilot randomized controlled trial of a mobile health exercise intervention for older patients with myeloid neoplasms (GO-EXCAP 2). <i>Journal of Geriatric Oncology</i> , 2022, 13, 545-553.	1.0	2
11	Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated with Similar Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S279.	2.0	1
12	Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2020, 136, 20-21.	1.4	1
13	A Case of Acute Eosinophilic Leukemia with a Novel PHF6 Mutation. <i>Case Reports in Hematology</i> , 2021, 2021, 1-4.	0.4	0
14	Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for for Acute Leukemia and MDS. <i>Blood</i> , 2016, 128, 2278-2278.	1.4	0
15	Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2022, 63, 222-226.	1.3	0
16	Synchronous B-Cell Acute Lymphoblastic Leukemia and Serous Ovarian Carcinoma: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 1621-1626.	0.7	0
17	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 41-42.	1.4	0